Company intelligence / Profile preview

Vapotherm

Exeter, New Hampshire, United Statesvapotherm.com ↗

Ownership: Public · VAPO
Employees: ~116
Development stage: Other

Overview

Vapotherm’s high velocity therapy has been shown in randomized controlled trials to be non-inferior to noninvasive positive pressure ventilation (NiPPV) for preventing intubation in spontaneously breathing patients across age groups. The company’s devices are used worldwide and have treated over 4.1 million patients.

Therapeutic areas: Pulmonology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Onymos – partnership for IoT/cloud-connected medical device platform developmentPraxair – collaboration on heliox gas delivery with Precision Flow Heliox system

Financials

Market cap: $13.6M
Total revenue: $16.9M
Enterprise value: $133.3M

Beyond the preview

Go deeper on Vapotherm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vapotherm.

Explore the full profile